- Home
- TYL vs BMRN Comparison
TYL vs BMRN Comparison
Compare TYL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYL | BMRN |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 11.4B |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | TYL | BMRN |
|---|---|---|
| Price | $302.12 | $58.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 18 |
| Target Price | ★ $476.50 | $88.22 |
| AVG Volume (30 Days) | 763.6K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.01 | N/A |
| EPS | ★ 1.88 | 0.54 |
| Revenue | $493,101,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $9.55 | $15.02 |
| Revenue Next Year | $9.75 | $12.23 |
| P/E Ratio | $169.13 | ★ $110.20 |
| Revenue Growth | ★ 18.35 | 17.62 |
| 52 Week Low | $270.71 | $49.26 |
| 52 Week High | $621.34 | $66.28 |
Technical Indicators
Market Signals| Indicator | TYL | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 55.26 |
| Support Level | $294.36 | $54.24 |
| Resistance Level | $331.06 | $60.22 |
| Average True Range (ATR) | 11.29 | 1.41 |
| MACD | 0.74 | -0.13 |
| Stochastic Oscillator | 10.90 | 50.44 |
Price Performance
Historical ComparisonAbout TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.